Standout Papers

MONARCH 2: Abemaciclib in Com... 1997 2026 2006 2016 1.1k
  1. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy (2017)
    George W. Sledge, Masakazu Toi et al. Journal of Clinical Oncology
  2. Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199 (2014)
    Sylvia Adams, Robert J. Gray et al. Journal of Clinical Oncology
  3. Phase I Safety and Pharmacokinetic Study of Recombinant Human Anti-Vascular Endothelial Growth Factor in Patients With Advanced Cancer (2001)
    Michael S. Gordon, Kim Margolin et al. Journal of Clinical Oncology
  4. Liquid biopsy enters the clinic — implementation issues and future challenges (2021)
    Michail Ignatiadis, George W. Sledge et al. Nature Reviews Clinical Oncology
  5. Constitutive Activation of NF-κB during Progression of Breast Cancer to Hormone-Independent Growth (1997)
    Harikrishna Nakshatri, Poornima Bhat‐Nakshatri et al. Molecular and Cellular Biology
  6. Integrated digital error suppression for improved detection of circulating tumor DNA (2016)
    Aaron M. Newman, Alexander F. Lovejoy et al. Nature Biotechnology
  7. Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer (2010)
    Kimberly Blackwell, Harold J. Burstein et al. Journal of Clinical Oncology
  8. Weekly Paclitaxel in the Adjuvant Treatment of Breast Cancer (2008)
    Joseph A. Sparano, Molin Wang et al. New England Journal of Medicine
  9. Trastuzumab Plus Adjuvant Chemotherapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: Planned Joint Analysis of Overall Survival From NSABP B-31 and NCCTG N9831 (2014)
    Edith A. Perez, Edward H. Romond et al. Journal of Clinical Oncology
  10. Postmastectomy Radiotherapy: Clinical Practice Guidelines of the American Society of Clinical Oncology* (2001)
    Abram Recht, Stephen B. Edge et al. Journal of Clinical Oncology
  11. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 (2019)
    George W. Sledge, Masakazu Toi et al. JAMA Oncology
  12. Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193) (2003)
    George W. Sledge, Donna Neuberg et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 12 from Science/Nature 127 standout
Sub-graph 1 of 16

Citing Papers

Accurate proteome-wide missense variant effect prediction with AlphaMissense
2023 StandoutScienceNobel
CDK4 and CDK6 kinases: From basic science to cancer therapy
2022 StandoutScience
1 intermediate paper

Works of George W. Sledge being referenced

The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
2019 Standout
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
2017 Standout
and 1 more

Author Peers

Author Last Decade Papers Cites
George W. Sledge 14481 9362 7375 435 24.8k
Masakazu Toi 10580 6747 7817 651 20.9k
Ana M. González-Angulo 14849 11118 8771 278 24.6k
Lisa A. Carey 15568 11762 7082 412 25.0k
Karen A. Gelmon 15458 6840 5516 389 23.1k
Sibylle Loibl 19027 13044 5866 584 28.4k
Hiroji Iwata 16179 6860 4707 514 22.9k
Fátima Cardoso 13308 10189 7161 391 24.3k
Antonio C. Wolff 15460 10354 5361 352 24.0k
Jonas Bergh 15296 11360 10934 510 28.3k
Naoto T. Ueno 10744 6357 5453 537 19.9k

All Works

Loading papers...

Rankless by CCL
2026